Description
An inhibitor of HIV reverse transcriptase; inhibits HIV-1 replication in PBMCs (EC50 = 8.8 nM); reduces the synthesis of HIV-specific antigen in MT-4 cells at 0.1-10 µg/ml; reduces HIV-induced plaque formation in MT-4 cells at 0.05 µg/ml; reduces plasma- and cell-associated viral load in HIV-2-infected macaques; induces sustained hind paw mechanical allodynia in a rat model of ATN at a cumulative dose of 375 mg/kg
Formal name: 2′,3′-didehydro-3′-deoxy-thymidine
Synonyms: BMY 27857|d4T|NSC 163661
Molecular weight: 224.2
CAS: 3056-17-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)||Product Type|Biochemicals|Small Molecule Inhibitors|Reverse Transcriptases||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS||Research Area|Neuroscience|Pain Research